Search - tctmd.com

Displaying 41 - 60 of 259

Sort: Relevancy | Date

Atherosclerosis Progression May Share Traits With Tumor Growth

News Daily News

Atherosclerosis Progression May Share Traits With Tumor Growth

May 08, 2024

Time-Restricted Eating, High-Intensity Training Have Heart Benefits for Obese Women

News Daily News

Time-Restricted Eating, High-Intensity Training Have Heart Benefits for Obese Women

May 07, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

High Lp(a) Levels Harmful in Patients With and Without ASCVD

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

AHA Updates Its Scientific Statement on CIED Infections

News Daily News

AHA Updates Its Scientific Statement on CIED Infections

December 11, 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

TCTMD’s Top 10 Most Popular Stories for October 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

November 01, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

TCT 140: Combined Coexistence of Multiple Vulnerable Plaque Features is Associated with Incremental Rates of Adverse Events in Patients with Diabetes Mellitus. New Insights From the COMBINE OCT-FFR trial

Presentation TCT 2023

TCT 140: Combined Coexistence of Multiple Vulnerable Plaque Features is Associated with Incremental Rates of Adverse Events in Patients with Diabetes Mellitus. New Insights From the COMBINE OCT-FFR trial

Presenter: David del Val

October 25, 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Combined Surgical and Catheter Ablation Best for Persistent AF

News Conference News EACTS 2023

Combined Surgical and Catheter Ablation Best for Persistent AF

Michael O'Riordan

October 12, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Vegetarian Diets May Curb Cardiometabolic Risk: Meta-analysis

News Daily News

Vegetarian Diets May Curb Cardiometabolic Risk: Meta-analysis

August 01, 2023

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

News Daily News

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

July 26, 2023

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

July 17, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.